Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Deferred Taxes: 2020-2024

Historic Deferred Taxes for Maravai Lifesciences Holdings (MRVI) over the last 4 years, with Dec 2024 value amounting to $11,000.

  • Maravai Lifesciences Holdings' Deferred Taxes fell 100.00% to $11,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $756.5 million, marking a year-over-year increase of 0.20%. This contributed to the annual value of $11,000 for FY2024, which is 100.00% down from last year.
  • According to the latest figures from Q4 2024, Maravai Lifesciences Holdings' Deferred Taxes is $11,000, which was down 100.00% from $764.8 million recorded in Q4 2023.
  • Maravai Lifesciences Holdings' 5-year Deferred Taxes high stood at $764.8 million for Q4 2023, and its period low was -$5.5 million during Q3 2023.
  • Moreover, its 3-year median value for Deferred Taxes was $7.0 million (2022), whereas its average is $88.6 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Deferred Taxes soared by 1,122,800.00% in 2021 and then tumbled by 159.91% in 2023.
  • Maravai Lifesciences Holdings' Deferred Taxes (Quarterly) stood at -$4.2 million in 2020, then spiked by 516.95% to $17.5 million in 2021, then slumped by 59.86% to $7.0 million in 2022, then spiked by 10,807.86% to $764.8 million in 2023, then tumbled by 100.00% to $11,000 in 2024.
  • Its last three reported values are $11,000 in Q4 2024, $764.8 million for Q4 2023, and -$5.5 million during Q3 2023.